Teleflex raises 2026 profit forecast as Q3 profit tops estimates
Teleflex raised its 2026 adjusted EPS forecast to $7.50 to $7.75 and reported Q3 adjusted EPS of $2.63, against a $1.92 consensus estimate. Revenue of $567.8 million was in line with the $572.44 million estimate.
Key takeaways
- Teleflex (TFX) raised its 2026 adjusted EPS forecast to $7.50 to $7.75 after third-quarter adjusted EPS of $2.63 topped the $1.92 consensus estimate. Revenue was $567.8 million, in line with the $572.44 million estimate. The company kept its 3.5% to 4.5% pro forma adjusted constant currency revenue growth forecast.
Teleflex (TFX) raised its 2026 adjusted earnings forecast after third-quarter adjusted EPS of $2.63 topped the $1.92 consensus estimate.
Shares rose 1.5% at 3:59 p.m. ET, from a $149.87 close.
Here's how the company did:
- Adjusted EPS: $2.63 vs. $1.89 a year earlier, topping the $1.92 consensus estimate
- GAAP EPS from continuing operations: $1.30 vs. a loss of $1.32 a year earlier
- Revenue: $567.8 million vs. $566.9 million a year earlier, in line with the $572.44 million consensus estimate
Revenue rose 0.2% from a year earlier and 3.0% on a pro forma adjusted constant currency basis.
Adjusted operating margin was 25.0%, up from 22.0% a year earlier. Adjusted gross margin was 66.8%.
2026 guidance
Teleflex now expects 2026 adjusted diluted EPS from continuing operations of $7.50 to $7.75, up from $6.90 to $7.20 on Aug. 6.
GAAP EPS from continuing operations is now forecast at $2.84 to $3.09, up from $2.54 to $2.84.
GAAP revenue growth is now forecast at 13.2% to 14.2%, down from 13.4% to 14.4%, on changes in foreign exchange rates. Pro forma adjusted constant currency revenue growth stays at 3.5% to 4.5%.
CEO Jason Weidman said: “Reflecting our third quarter progress, we are raising our full-year adjusted earnings per share guidance.”
Segment results
Vascular revenue rose 4.7% to $243.5 million. Surgical revenue rose 4.2% to $114.0 million.
Interventional revenue fell 2.6% to $210.3 million. On a pro forma adjusted constant currency basis, Interventional grew 0.2%.
The company now reports three global business units: Vascular, Interventional and Surgical. Earlier periods were restated to match.
Divestitures and buybacks
The sale of its OEM business to Montagu and Kohlberg was completed on Aug. 3, 2026, for $1.5 billion in cash. After-tax proceeds were $1.25 billion.
The sale of its Acute Care and Interventional Urology businesses to Intersurgical Ltd. is pending. The company continues to work toward closing by the end of 2026, and closing may extend into 2027.
From July 1, 2026 through the release date, the company repurchased $350 million of its common stock, including a $250 million accelerated share repurchase. $400 million remains under the $1 billion authorization approved on Dec. 9, 2025.
The company repaid its $700 million Term Loan A-2 in August.
Net income has moved from a loss of $8.2 million in the first quarter of 2026 to a profit of $99.7 million in the second quarter.